AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18382805
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (for patients who failed to respond to placebo)
Trial: 11850288
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg telithromycin, once daily for 5 days (Group A)
Trial: 11850288
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg telithromycin, once daily for 5 days (Group B)
Trial: 11850288
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg telithromycin, once daily for 5 days (Group C)
Trial: 11850288
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg telithromycin, once daily for 5 days (Group D)
Trial: 12047398
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 microg) administered during insulin clamp studies
Trial: 12047398
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without misoprostol) during insulin clamp studies
Trial: 9583286
Drug: Fibrinogen levels
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen levels (374 +/- 11.9 mg/dL)
Trial: 9583286
Drug: Fibrinogen levels
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen levels > 300 mg percent
Trial: 2768616
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg methylphenidate (Ritalin)
Trial: 2768616
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg methylphenidate (Ritalin)
Trial: 687500
Drug: Ephedrine 60
RxNorm normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 60 or 90 mg
Trial: 687500
Drug: Pseudoephedrine 210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 210 or 240 mg
Trial: 687500
Drug: Ephedrine 60
RxNorm normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 60 mg
Trial: 687500
Drug: Pseudoephedrine 210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 210 mg
Trial: 23377843
Drug: Common identity
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common identity treatment (to enhance their sense of commonality)
Trial: 19243891
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration (0.6 g/kg)
Trial: 11349340
Drug: Weekly communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly communication for 6 months via a totally automated, computer‐based voice system.
Trial: 8270918
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (antibiotic treatment for asymptomatic UTI)
Trial: 2887520
Drug: bopindolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bopindolol (1 to 4 mg/day)
Trial: 2887520
Drug: atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50 to 200 mg/day)
Trial: 29624493
Drug: Pazufloxacin 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazufloxacin 0.6% BID (twice a day)
Trial: 26847148
Drug: LC (Traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC (Traditional Chinese Medicine)
Trial: 26847148
Drug: Placebo (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (standard treatment without LC)
Trial: 25385295
Drug: hUC‐MSC therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hUC‐MSC therapy with anti‐inflammatory treatment
Trial: 25385295
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti‐inflammatory treatment only)
Trial: 23209076
Drug: C312M vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C312M vaccination via oral, immersion, and oral plus immersion routes
Trial: 16206349
Drug: 4 weekly
RxNorm normalized name: TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weekly HMW hyaluronan injections (O4, n = 128)
Trial: 16206349
Drug: 3 weekly
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 weekly HMW hyaluronan injections followed by one arthrocentesis (O3A1, n = 120)
Trial: 16206349
Drug: 4 arthrocenteses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 arthrocenteses without injection (control group, A4, n = 124)
Trial: 16206349
Drug: 4 weekly
RxNorm normalized name: TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weekly HMW hyaluronan injections (O4)
Trial: 3317337
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg b.i.d.
Trial: 6362699
Drug: Brotizolam 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.5 mg
Trial: 3531851
Drug: PK10169 low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK10169 low-molecular-weight heparin
Trial: 25707875
Drug: Overall graft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall graft survival at 5 years with either induction therapy
Trial: 17595381
Drug: Constraint-induced movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced movement therapy (CIMT) for 2 weeks
Trial: 16815320
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg sumatriptan
Trial: 23325368
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sumatriptan
Trial: 12665269
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (Fluvent) at a daily dose of 22 microg
Trial: 12665269
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (Becotide) at a daily dose of 400 microg
Trial: 25853591
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and protamine
Trial: 7100
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg metoprolol t.i.d.
Trial: 29901379
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg, 1 tablet a day for 4 weeks, then increased to 2 tablets a day for the next 4 weeks)
Trial: 29901379
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same dosing schedule as donepezil)
Trial: 20456105
Drug: Pads with
RxNorm normalized name: Sani-pads with Aloe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pads with different amounts of lotion applied; evaluated for 3 hours using the BTK protocol.
Trial: 20456105
Drug: Pads with
RxNorm normalized name: Sani-pads with Aloe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pads with AGM core; evaluated for lotion transfer.
Trial: 20456105
Drug: Pads with
RxNorm normalized name: Sani-pads with Aloe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pads with cellulose core; evaluated for lotion transfer.
Trial: 20456105
Drug: Clinical in-use
RxNorm normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical in-use study on second series of test products; evaluated for lotion transfer.
Trial: 18513551
Drug: Capsule endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule endoscopy after an 8-hour fasting period (Group A)
Trial: 18513551
Drug: Capsule endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule endoscopy after drinking 2 doses of 45 mL oral sodium phosphate (NaP) (Group B)
Trial: 18513551
Drug: Capsule endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule endoscopy (both groups)
Trial: 16129742
Drug: Calcium phosphate
RxNorm normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium phosphate degradable cement (Norian SRS) augmentation
Trial: 12860582
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride 1500 mg with chondroitin sulfate 1200 mg
Trial: 9264422
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy (antiarrhythmic drug therapy)
Trial: 7486901
Drug: Clarithromycin (CAM)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (CAM) 100 mg, twice a day for 8 weeks
Trial: 2344171
Drug: Cefonicid (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (one daily intravenous dose)
Trial: 29117996
Drug: Isolated ultrafiltration
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated ultrafiltration (ultrafiltration rate 13.6 ± 3.9 ml·kg⁻¹·h⁻¹)
Trial: 18092695
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (percutaneous Kirschner-wiring)
Trial: 18092695
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (close reduction and immobilisation in plaster splint)
Trial: 15946977
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m(2) on days 1 and 8 and epirubicin 60 mg/m(2) on day 1, 3 weekly for six cycles (VE)
Trial: 15946977
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) i.v. on day 1, 3 weekly for six cycles (AC)
Trial: 11828245
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g x d(‐1) during 5 d)
Trial: 8733874
Drug: Moderate hypothyroidism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hypothyroidism induced by half-dose thyroxine replacement therapy (cutting replacement therapy in half)
Trial: 8733874
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation (substituting triiodothyronine for thyroxine replacement over a 3-week period, then omitting hormone therapy for 3 weeks)
Trial: 1715416
Drug: PEB chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEB chemotherapy (group B)
Trial: 29989468
Drug: Multifactorial program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial program (exercise, medication review, and education)
Trial: 26789749
Drug: School-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based treatment (SBT) with praziquantel, coverage 84.2%.
Trial: 24504198
Drug: Sinusoidal linear
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinusoidal linear acceleration at 30 mG
Trial: 24504198
Drug: Sinusoidal linear
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinusoidal linear acceleration at 1.25 mG
Trial: 24504198
Drug: Sinusoidal linear
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinusoidal linear acceleration at 10 mG
Trial: 24504198
Drug: Sinusoidal linear
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinusoidal linear acceleration at 6.5 mG
Trial: 17327294
Drug: Tobramycin 6
RxNorm normalized name: tobramycin 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 6 mg/kg once daily plus penicillin G 5 million IU x 4
Trial: 17327294
Drug: Tobramycin 6
RxNorm normalized name: tobramycin 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 6 mg/kg three times daily plus penicillin G 5 million IU x 4
Trial: 16277774
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with lowest bioavailability
Trial: 16277774
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with highest bioavailability
Trial: 10467991
Drug: Low-fat milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat milk (1.0 g fat/dl, 3.3 g protein/dl)
Trial: 10467991
Drug: Standard-fat milk
RxNorm normalized name: MILK FAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-fat milk (3.5 g fat/dl, 3.3 g protein/dl)
Trial: 10467991
Drug: Partially vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially vegetable fat and protein-reduced milk (3.5 g fat/dl, 50% vegetable; 2.2 g protein/dl)
Trial: 10467991
Drug: Full-vegetable-fat milk
RxNorm normalized name: MILK FAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-vegetable-fat milk (3.5 g fat/dl, 100% vegetable; 3.0 g protein/dl)
Trial: 2894993
Drug: WAL801 CL
RxNorm normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WAL801 CL 8 mg b.d. for 15 days
Trial: 27080209
Drug: E6005 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6005 ointment (0.2%)
Trial: 20175714
Drug: Perindopril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril plus diuretic combination therapy
Trial: 20175714
Drug: Perindopril monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril monotherapy
Trial: 17910536
Drug: Intervention programme
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention programme (15 weekly lessons of 1 hour each for 3 months)
Trial: 10096374
Drug: finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: finasteride 5 mg daily
Trial: 6282455
Drug: MACC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MACC chemotherapy only (methotrexate, doxorubicin, cyclophosphamide, and lomustine)
Trial: 26163437
Drug: Cisplatin-chemoradiotherapy (CRT)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-chemoradiotherapy (CRT) with weekly cisplatin (30 mg/m(2)/w)
Trial: 26163437
Drug: Cetuximab-radiotherapy (ERT)
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab-radiotherapy (ERT) with loading dose of 400 mg/m(2) followed by weekly doses of 250 mg/m(2)
Trial: 19369376
Drug: High micronutrient
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High micronutrient treatment (100% RDA)
Trial: 19369376
Drug: Low micronutrient
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low micronutrient treatment (15% RDA)
Trial: 19369376
Drug: n-3 treatments
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 treatments (900 mg alpha-linolenic acid + 100 mg docosahexaenoic acid or 140 mg alpha-linolenic acid)
Trial: 14762227
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg q.d. a.m.
Trial: 14762227
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg q.d. p.m.
Trial: 19269020
Drug: Celecoxib 100
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 mg b.i.d.
Trial: 11241051
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy (0.074 mg/kg, subcutaneously, 3 times per week)
Trial: 9152782
Drug: Captopril (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (37.5 mg daily)
Trial: 675213
Drug: fenoterol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoterol (1.25 mg)
Trial: 675213
Drug: reproterol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reproterol (2.5 mg)
Trial: 675213
Drug: terbutaline (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline (2.5 mg)
Trial: 675213
Drug: salbutamol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol (1.25 mg)
Trial: 30945505
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with medication (Diclofenac Diethylamine Emulgel, 3 times a day for 2 weeks)
Trial: 30945505
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Diclofenac Diethylamine Emulgel, 3 times a day for 2 weeks)
Trial: 25935840
Drug: Sugammadex (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (2 or 4 mg kg(‐1))
Trial: 21546719
Drug: Antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy (vitamin A, vitamin C, vitamin E)
Trial: 17517850
Drug: Tafenoquine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine (200 mg loading dose daily for 3 days, followed by 200 mg weekly for 6 months)
Trial: 11549646
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 or 120 mg/d)
Trial: 9542478
Drug: Zolmitriptan 15
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 15 mg
Trial: 7864934
Drug: simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 20 mg daily
Trial: 3212150
Drug: Amitriptyline (37.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (37.5, 70 mg)
Trial: 3212150
Drug: Trazodone (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (100, 200 mg)
Trial: 3212150
Drug: Viloxazine (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine (100, 200 mg)
Trial: 3212150
Drug: Protriptyline (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protriptyline (10, 20 mg)
Trial: 27995519
Drug: Lanreotide 120
RxNorm normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 120 mg subcutaneously every 28 days
Trial: 23340530
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency (PRF) at 42° C for 120 seconds, applied twice, once a week for 3 weeks.
Trial: 21907499
Drug: Involuntary medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involuntary medication treatment
Trial: 17127797
Drug: Ethanol dose
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol dose 1-2 ml (Group A)
Trial: 17127797
Drug: Ethanol dose
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol dose >2 ml (Group B)
Trial: 15262845
Drug: Sirolimus 3
RxNorm normalized name: temsirolimus 30 mg/3 mL (10 mg/mL) (first dilution) INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus 3 mg/d
Trial: 15262845
Drug: Sirolimus 5
RxNorm normalized name: SIROLIMUS 5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [FYARRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus 5 mg/d
Trial: 30388182
Drug: Quit preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quit preparation module
Trial: 22803422
Drug: Acupoint heat-sensitization
RxNorm normalized name: heather pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint heat-sensitization moxibustion (Group A), once daily for 4 weeks
Trial: 22803422
Drug: Changtai Oral
RxNorm normalized name: CALCIUM 0.99 ORAL TABLET [HANTAI 8030 Ca-D3 GOLD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changtai Oral Liquid (Group B), 10 mL three times daily for 4 weeks
Trial: 22803422
Drug: Changtai Oral
RxNorm normalized name: CALCIUM 0.99 ORAL TABLET [HANTAI 8030 Ca-D3 GOLD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changtai Oral Liquid (Group B)
Trial: 12121581
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry tablets (taken twice daily)
Trial: 12121581
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (250 ml three times daily)
Trial: 12121581
Drug: Placebo (juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (juice + tablets)
Trial: 19935757
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry tablets
Trial: 12121581
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry tablets vs. cranberry juice
Trial: 12121581
Drug: Both cranberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both cranberry juice and cranberry tablets
Trial: 11226996
Drug: Metoclopramide (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (0.25 mg/kg)